Financial Data and Key Metrics Changes - The company reported full-year revenue of $40.9 million, representing a 26% growth over 2024 [5][21] - Fourth quarter revenue was $11.4 million, the highest revenue quarter of the year, up 13% from the third quarter but down slightly year-over-year [15][19] - Gross margin for the fourth quarter was 68.6%, down from 71.4% a year ago, but up from 63.8% in the third quarter [19][21] - Operating loss for the fourth quarter was $2.8 million, compared to an operating loss of about $200,000 in the prior year quarter [20][21] - Net loss for the fourth quarter was $3.8 million, or $0.09 per share, compared to a net loss of $300,000 or $0.01 per share for the same quarter last year [20][21] Business Line Data and Key Metrics Changes - The U.S. Orthotics and Prosthetics (O&P) channel achieved quarterly revenue exceeding $1 million for the first time, up 81% year-over-year [7][18] - International revenue reached a record $2.2 million, up 46% year-over-year, representing 19% of total revenue [18] - The company recorded 241 MyoPros ordered during the fourth quarter, up 5% sequentially from the third quarter [5][19] - Recurring patient sources, including referrals under the MyoConnect program, represented 42% of fourth quarter revenue, up from 26% in the fourth quarter of 2024 [8][18] Market Data and Key Metrics Changes - The company signed in-network contracts with additional Medicare Advantage and commercial payers, including a multi-state agreement with Elevance Health covering 45 million lives [10][11] - The patient pipeline stood at 1,528 patients as of December 31, 2025, an increase of 10% year-over-year [18] - The company faced challenges with Medicare Advantage payers, which issued a high number of pre-authorization denials [16][17] Company Strategy and Development Direction - The company aims to grow revenue through direct-to-patient marketing and expand orders from recurring sources [4] - A strategic pivot towards recurring patient sources is evident, with a focus on the MyoConnect program to engage therapists and physicians [8][12] - The company plans to limit advertising spending while building out the MyoConnect program and adding direct sales resources [23] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in the O&P channel and international markets, despite challenges with Medicare Advantage [10][17] - The company expects revenue in 2026 to be in the range of $43 million to $46 million, with a focus on recurring sources [23][24] - Management anticipates a reduction in cash burn by roughly half in 2026 compared to 2025 [24] Other Important Information - The company launched the MyoPro Center of Excellence program to educate O&P practices on the new MyoPro 2X product [6] - A randomized controlled trial is being conducted to further validate the MyoPro's effectiveness, with results expected by the end of the year [79] Q&A Session Summary Question: What drove the increase in cost per pipeline ad in the MyoConnect program? - Management noted that the fourth quarter typically has higher advertising costs due to competition and that a new marketing head and agency have been brought on to address this [34][35] Question: Can you provide KPIs around the O&P channel? - The company has trained and certified a couple of dozen O&P providers, generating over $1 million in revenue in the quarter [38][39] Question: What are the assumptions for the U.S. O&P business in 2026 guidance? - Growth is expected in the O&P channel and international markets, while direct billing is anticipated to remain flat [41][42] Question: What is the status of the pipeline ads and dropout rate? - The pipeline ads were lower due to a shutdown in late December, and the dropout rate was noted to be around 20% [46][50] Question: How is the German market performing? - The German market is growing well due to favorable reimbursement policies and a strong recruitment of O&P practices [78] Question: What is the timeline for the MyoPro 3 model? - The MyoPro 3 will be a next-generation platform with significant improvements, but specific timelines were not provided [81]